NASDAQ · NVNO
enVVeno Medical Corporation
$7.02+$0.28 (+4.08%)
enVVeno Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.37% below the high.
Loading market information…
OTC · TOMDF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Todos Medical Ltd.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Todos Medical Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Todos Medical Ltd. operates as an in vitro diagnostics company, concentrating on the creation and commercialization of blood tests for the early detection of cancer and Alzheimer's disease, primarily serving the United States market. The company's innovative approaches to cancer diagnostics include the Total Biochemical Infrared Analysis (TBIA), a proprietary screening technology that uses peripheral blood spectroscopy to investigate cancer's effects on the immune system. Another key offering is the Lymphocyte Proliferation Test (LPT), a diagnostic blood assay designed to assess how peripheral blood lymphocytes and monocytes react to exogenous mitogenic stimulation, which induces cell cycle entry. Their cancer product lineup includes TM-B1 and TM-B2 for breast cancer screening, alongside the TMC blood test for diagnosing colon cancer. Beyond oncology, Todos Medical is also actively developing blood-based tests for identifying neurodegenerative conditions, notably Alzheimer's disease. In addition to its diagnostic portfolio, the company markets Tollovid, a dietary supplement acting as a 3CL protease inhibitor, formulated to bolster a healthy immune response against common coronaviruses. Furthermore, Tollovir, an antiviral treatment for Covid-19, is currently progressing through Phase 2 clinical trials. Todos Medical Ltd. engages in strategic alliances, including a collaboration with Integrated Health LLC, and has various agreements in place for developing SARS-nCoV-2 screening tests and distributing specific COVID-19 test kits. The company was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.02+$0.28 (+4.08%)
enVVeno Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.37% below the high.
$0.00$0.00 (0.0%)
Banyan Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
BioLife Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00$0.00 (0.0%)
VMS Rehab Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.02$0.00 (0.0%)
Easy Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Golden Developing Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
ScripsAmerica, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Bioasis Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
